SEC Filing Summary: Spyre Therapeutics, Inc. (SYRE)
Business Context and Reporting Period
This Form 8-K was filed by Spyre Therapeutics, Inc. on January 16, 2024. The report details a corporate governance event regarding the listing status of the Company's common stock on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing transfer and does not contain financial performance data.
Material Changes
- Listing Transfer: The Company received approval to transfer its common stock listing from The Nasdaq Capital Market to The Nasdaq Global Select Market.
- Effective Date: The transfer became effective at the opening of business on January 19, 2024.
- Trading Symbol: The stock will continue to trade under the symbol "SYRE."
Outlook, Risks, and Management Commentary
Management notes that The Nasdaq Global Select Market operates in substantially the same manner as The Nasdaq Capital Market. The Company must continue to meet specific financial requirements and comply with Nasdaq's corporate governance standards. No specific risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Confirm the effective date of the listing transfer (January 19, 2024).
- Verify that the trading symbol remains "SYRE" on The Nasdaq Global Select Market.
- Review the specific financial and corporate governance requirements for The Nasdaq Global Select Market to ensure continued compliance.